Masato Hayakawa

Partner | Tokyo
|
81 3 3214 6522

Experience

Represented Santen Pharmaceutical Co., Ltd. (TYO: 4536) in its $225 million acquisition of all outstanding shares of Eyevance Pharmaceuticals Holdings Inc., a Texas-based distributor of ophthalmological medicines, making it a wholly owned subsidiary of Santen.

Represented Ping An Insurance (Group) Company of China Ltd. in its US$780 million collaboration with Japanese pharmaceutical company Shionogi & Co., Ltd., to develop and distribute new drugs and healthcare products throughout China and Southeast Asia.

Represented Fujifilm and Fuji Xerox, a joint venture between Fujifilm and Xerox, in connection with the acquisition by Fujifilm of Xerox's stake in Fuji Xerox and the related arrangements to use the Xerox brand, cross license technology, and establish a long term procurement and services relationship.

Represented Taisho Pharmaceutical in the purchase of French-based pharmaceutical manufacturer UPSA from Bristol-Myers Squibb for $1.6 billion, including the transfer and licensing of trademarks, marketing authorizations, and other intellectual property.

Represented Renesas Electronics Corporation on the IP and commercial aspects of its $6.7 billion acquisition of NASDAQ-listed Integrated Device Technology (IDT), a market-leading analog mixed-signal company, to create market-leading embedded solution capabilities.

Represented Elixirgen, a Maryland-based biotechnology start-up focused on stem cell related technologies, in its strategic business partnership with Ricoh to co-develop cell-based nano-printing technology to support drug discovery. As part of the partnership agreement, Ricoh will acquire a 34.5% stake in Elixirgen.

Represented Fujitsu in its strategic partnership with Ericsson to develop, manufacture, commercialize and deliver end-to-end 5G network solutions and related services to major telecom service providers.

Represented Nissan Motor on the IP and commercial aspects of the sale of its electric battery operations and production facilities to Envision Group, a Chinese renewable energy firm. The transaction included the sale of Nissan’s lithium-ion battery joint venture with NEC Corporation, Automotive Energy Supply Corporation, along with Nissan’s battery manufacturing operations in Japan, the U.S. and the UK.

Represented Nissan Motor in its initiative with DeNA to develop, field test, and manufacture self-driving vehicles and launch Easy Ride, a driverless mobility-as-a-service business.

Represented Renesas Electronics Corporation on the IP and commercial aspects of its $3.2 billion acquisition of listed U.S. semiconductor developer Intersil Corporation, a leading supplier of semiconductors to the automotive industry.

Represented BiomX, an emerging Israeli life sciences company that is developing new drugs for inflammatory bowel disease and cancer, in its exclusive development and commercialization agreement with Keio University to license BiomX to develop pharmaceuticals based on bacterial strains developed by Keio University.

Represented NanoCarrier, a Japanese oncology start-up, in its exclusive license and supply agreement with Israeli biopharmaceutical company, VBL Therapeutics, to co-develop and co-commercialize an anticancer therapeutic candidate.


Asian Legal Business 2021

Asia’s Top 15 TMT Lawyers